Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II rec...
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
- Associated Therapies
- -
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 256
- Registration Number
- NCT00765947
- Locations
- 🇸🇰
Investigative Site, Bratislava, Slovakia
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 451
- Registration Number
- NCT00760266
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Regression of Fatty Heart by Valsartan Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT00745953
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 231
- Registration Number
- NCT00744237
- Locations
- 🇺🇸
Forest Investigative Site 49, Tustin, California, United States
🇺🇸Forest Investigative Site 32, Pembroke Pines, Florida, United States
🇺🇸Forest Investigative Site 081, Pembroke Pines, Florida, United States
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 384
- Registration Number
- NCT00698646
- Locations
- 🇺🇸
Investigative Site, Taylors, South Carolina, United States
🇺🇸Investigative Sites, Pismo Beach, California, United States
🇺🇸Investigative site, St George, Utah, United States
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 564
- Registration Number
- NCT00667719
- Locations
- 🇹🇷
Investigative Site, Turkey, Turkey
Black Education and Treatment of Hypertension (BEAT HTN)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 99
- Registration Number
- NCT00661895
- Locations
- 🇺🇸
Creighton Community Health Center, Omaha, Nebraska, United States
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2010-07-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 207
- Registration Number
- NCT00654745
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2500
- Registration Number
- NCT00649389
Factorial Study of Metoprolol Succinate TOPROL-XL (324A)
- Conditions
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1900
- Registration Number
- NCT00642096
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.